Compare Novavax Inc (NVAX) vs Veritone Inc (VERI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novavax Inc vs Veritone Inc — how do they compare? Novavax Inc trades at $12.04 (market cap $1.82B), while Veritone Inc trades at $0.58 (market cap $59.46M). The key difference: Novavax Inc is far larger — about 30.6× Veritone Inc's market cap, and Novavax Inc is trading nearer its 52-week high, Veritone Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Novavax Inc for 59 Days and Veritone Inc for 12 Days on average.
| NVAX | VERI | |
|---|---|---|
Market Cap | $1.82B | $59.46M |
Volume | 6,198,505 | 15,523,164 |
Sector | Health | Technology |
52-Week High | $12.56 | $8.39 |
52-Week Low | $6.22 | $0.59 |
Typical Hold Time | 59 Days | 12 Days |
Enterprise Value | $1.39B | $94.86M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novavax (NVAX) trades at $11.22, down 0.88% on the day, with a bullish technical signal from moving averages and a neutral RSI. The company reported strong revenue of $1.12 billion in 2025 and a net income of $440.30 million, but faces negative cash flow and a projected net loss for 2026. Recent news highlights its strategic pivot to a partnership-driven model using its Matrix-M adjuvant technology, with regulatory approvals for its updated COVID-19 vaccine in key markets.
The outlook for NVAX is mixed, with analyst consensus strongly favoring a buy rating (73.92%) but significant financial risks including negative equity, persistent cash burn, and volatile earnings. Investment opportunity lies in the successful execution of its licensing strategy and expansion into oncology, though execution risks and competitive pressures remain key concerns for shareholders.
Veritone (VERI) trades at $0.61, down 11.76% in the last 24 hours, reflecting bearish technical signals. The company reported a net loss of $111.73 million in 2025, with negative profit margins and cash flow challenges, though revenue remains near $92 million. Recent news includes a $15 million equity offering and partnerships, but legal investigations and persistent losses weigh on sentiment.
The outlook is highly speculative, with a consensus price target of $3.75 suggesting significant upside if the company achieves profitability. However, high execution risk, cash burn, and legal overhangs present substantial downside, making the stock suitable only for risk-tolerant investors betting on a turnaround.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novavax Inc
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →About Veritone Inc
Veritone is a leading provider of enterprise AI software and solutions, centered on its proprietary AI operating system, aiWARE™. The platform orchestrates a vast ecosystem of machine learning models to transform unstructured data—such as audio, video, and text—into actionable intelligence. Serving the media, entertainment, and public sectors, Veritone is a critical infrastructure partner for organizations looking to monetize data archives and operationalize AI at scale.
Read more on VERI →
